Drugs / Trifluorouracil tepidopyrimidine
Trifluorouracil tepidopyrimidine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06764680 | Dec 2024 → Jun 2026 overdue | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluorouracil tepidopyrimidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06764680 ↗ |
| Known as | Trifluridine tepipiridine | “Trifluridine tepipiridine consists of FTD and TPI, FTD can replace thymine into the DNA double-stranded to play an anti-tumor effect, while TPI can inhibit thymidine...” NCT06764680 ↗ |
| Known as | Trifluridine-tipyrimidine | “Trifluridine-tipyrimidine is a new oral cytotoxic chemotherapy drug.” NCT06764680 ↗ |
| Action | Inhibit | “while TPI can inhibit thymidine phosphorylase activity” NCT06764680 ↗ |
| Route | Oral | “30mg/m2. P.O. bid. d1-d5 and d15-d19. q4w” NCT06764680 ↗ |